Methods for reducing or alleviating inflammation in the digestive tract
AssigneeCase Western Reserve University
InventorsAlexander Rodriguez-Palacios, Fabio Cominelli
Life of this patent
Estimating the term…
Abstract
One aspect of the present disclosure can include a method for reducing or alleviating inflammation in the digestive tract of a subject in need thereof that consumes a disruptive dietary component. One step of the method can include assaying a previously obtained fecal sample from the subject for the presence of one or more Proteobacteria and an activity level of a peroxidase enzyme. The subject can decrease ingestion of the disruptive dietary component if the assayed presence of the one or more Proteobacteria and the activity level of the peroxidase enzyme are increased as compared to control levels.
Claims9
A method for reducing or alleviating inflammation in the digestive tract of a subject in need thereof that consumes a disruptive dietary component, the method comprising:
- assaying a previously obtained fecal sample from the subject for the presence of one or more gram-negative Proteobacteria and an activity level of a peroxidase enzyme;
- and
- decreasing ingestion of the disruptive dietary component by the subject in which the abundance of the one or more gram-negative Proteobacteria and the activity level of the peroxidase enzyme are increased as compared to control levels;
- wherein the subject is suffering from, or suspected of suffering from, inflammation in the digestive tract;
- wherein the disruptive dietary component is a non-caloric artificial sweetener selected from the group consisting of sucralose, maltodextrin, saccharin, acesulfame, aspartame, neotame, and combinations thereof.
A method for reducing or alleviating inflammation in the digestive tract of a subject in need thereof that consumes a non-caloric artificial sweetener, the method comprising:
- assaying a previously obtained fecal sample from the subject for the presence of E. coli and an activity level of myeloperoxidase (MPO);
- and
- decreasing ingestion of the non-caloric artificial sweetener by the subject in which the abundance of the E. coli and the activity level of the MPO are increased as compared to control levels;
- wherein the subject is suffering from, or suspected of suffering from, inflammatory bowel disease.
Dependencies are inferred from the claim text.